Mycophenolate Mofetil Ameliorates Diabetic Nephropathy in db/db Mice
Table 1
The clinical parameters of study groups.
Characteristics
Week
db/m
db/db
db/db + MMF
Body weight (g)
8 20
27.7 ± 0.25 31.4 ± 0.5
42.9 ± 1.76 51.0 ± 3.2
45.2 ± 0.37 50.1 ± 1.9
Daily food intake (g/day)
8 20
3.97 ± 0.01 5.6 ± 0.4
5.82 ± 0.28 7.6 ± 1.2
5.76 ± 0.17 8.8 ± 0.8
Daily water intake (mL/day)
20
5.0 ± 0.3
13.5 ± 0.6
15.6 ± 1.6
Urine output (mL/day)
20
0.4 ± 0.2
2.4 ± 1.4
7.5 ± 3
Fasting glucose (mg/dL)
20
95.8 ± 14.4
391 ± 40.6
434.9 ± 40.7
Kidney/BW (%)
20
1.54 ± 0.04
1.33 ± 0.17
1.05 ± 0.02
Liver/BW (%)
20
4.85 ± 0.65
5.9 ± 0.33
6.1 ± 0.38
Fat/BW (%)
20
3.2 ± 0.5
4.9 ± 0.17
6.3 ± 0.6
MMF: mycophenolate mofetil. The results are expressed as the mean ± S.E.M. Significantly different with respect to the db/m mice; #significantly different with respect to db/db mice. < 0.05.